{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:51:12Z","timestamp":1776174672474,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02336"],"award-info":[{"award-number":["24K02336"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K22079"],"award-info":[{"award-number":["24K22079"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K07182"],"award-info":[{"award-number":["22K07182"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K10503"],"award-info":[{"award-number":["25K10503"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015120","name":"Daiko Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015120","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,5,5]]},"DOI":"10.1038\/s41416-026-03369-2","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:12:12Z","timestamp":1772835132000},"page":"1276-1288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced nuclear export caused by O-GlcNAcylation of nucleoporins is a potential therapeutic target in mesothelioma"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7988-6634","authenticated-orcid":false,"given":"Satomi","family":"Mukai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-1794","authenticated-orcid":false,"given":"Tatsuhiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kagayaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-4440","authenticated-orcid":false,"given":"Emi","family":"Mishiro-Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Kondo-Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Yabuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-3848","authenticated-orcid":false,"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"3369_CR1","first-page":"402","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr., Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329.","journal-title":"CA Cancer J Clin"},{"key":"3369_CR2","doi-asserted-by":"crossref","unstructured":"Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev. 2021;30:200226.","DOI":"10.1183\/16000617.0226-2020"},{"key":"3369_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"3369_CR4","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55:1227\u201331.","journal-title":"Cancer Res"},{"key":"3369_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71:873\u201383.","journal-title":"Cancer Res"},{"key":"3369_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/onc.2013.528","volume":"34","author":"I Tanaka","year":"2015","unstructured":"Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, et al. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade. Oncogene. 2015;34:73\u201383.","journal-title":"Oncogene"},{"key":"3369_CR7","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","volume":"23","author":"R Tranchant","year":"2017","unstructured":"Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, et al. Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res. 2017;23:3191\u2013202.","journal-title":"Clin Cancer Res"},{"key":"3369_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"3369_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365.","journal-title":"Cancer Discov"},{"key":"3369_CR10","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1038\/onc.2012.5","volume":"31","author":"T Mizuno","year":"2012","unstructured":"Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene. 2012;31:5117\u201322.","journal-title":"Oncogene"},{"key":"3369_CR11","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41388-018-0417-7","volume":"38","author":"A Matsushita","year":"2019","unstructured":"Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, et al. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene. 2019;38:1966\u201378.","journal-title":"Oncogene"},{"key":"3369_CR12","doi-asserted-by":"crossref","unstructured":"Pobbati AV, Kumar R, Rubin BP, Hong W. Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem Sci. 2023;48:450\u201362.","DOI":"10.1016\/j.tibs.2022.12.005"},{"key":"3369_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fcell.2019.00156","volume":"7","author":"S Kakiuchi-Kiyota","year":"2019","unstructured":"Kakiuchi-Kiyota S, Schutten MM, Zhong Y, Crawford JJ, Dey A. Safety considerations in the development of Hippo pathway inhibitors in cancers. Front Cell Dev Biol. 2019;7:156.","journal-title":"Front Cell Dev Biol"},{"key":"3369_CR14","doi-asserted-by":"crossref","unstructured":"Akao K, Sato T, Mishiro-Sato E, Mukai S, Ghani FI, Kondo-Ida L, et al. TEAD-independent cell growth of Hippo-inactive mesothelioma cells: Unveiling resistance to TEAD inhibitor K-975 through MYC signaling activation. Mol Cancer Ther. 2024;24:709\u201319.","DOI":"10.1158\/1535-7163.c.7798925"},{"key":"3369_CR15","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/S0021-9258(17)43295-9","volume":"259","author":"CR Torres","year":"1984","unstructured":"Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;259:3308\u201317.","journal-title":"J Biol Chem"},{"key":"3369_CR16","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1016\/S0021-9258(19)57510-X","volume":"261","author":"GD Holt","year":"1986","unstructured":"Holt GD, Hart GW. The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J Biol Chem. 1986;261:8049\u201357.","journal-title":"J Biol Chem"},{"key":"3369_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrm.2017.22","volume":"18","author":"X Yang","year":"2017","unstructured":"Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017;18:452\u201365.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3369_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10020-022-00544-y","volume":"28","author":"Q Lu","year":"2022","unstructured":"Lu Q, Zhang X, Liang T, Bai X. O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Mol Med. 2022;28:115.","journal-title":"Mol Med"},{"key":"3369_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrc3114","volume":"11","author":"C Slawson","year":"2011","unstructured":"Slawson C, Hart GW. O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer. 2011;11:678\u201384.","journal-title":"Nat Rev Cancer"},{"key":"3369_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15280","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, et al. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280.","journal-title":"Nat Commun"},{"key":"3369_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.molcel.2017.10.010","volume":"68","author":"C Peng","year":"2017","unstructured":"Peng C, Zhu Y, Zhang W, Liao Q, Chen Y, Zhao X, et al. Regulation of the Hippo-YAP pathway by glucose sensor O-GlcNAcylation. Mol Cell. 2017;68:591\u2013604.e595.","journal-title":"Mol Cell"},{"key":"3369_CR22","doi-asserted-by":"publisher","first-page":"14259","DOI":"10.1073\/pnas.1913469117","volume":"117","author":"E Kim","year":"2020","unstructured":"Kim E, Kang JG, Kang MJ, Park JH, Kim YJ, Kweon TH, et al. O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proc Natl Acad Sci USA. 2020;117:14259\u201369.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3369_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/cas.12698","volume":"106","author":"S Hakiri","year":"2015","unstructured":"Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, et al. Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells. Cancer Sci. 2015;106:990\u20139.","journal-title":"Cancer Sci"},{"key":"3369_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.33594\/000000359","volume":"55","author":"A Sanjaya","year":"2021","unstructured":"Sanjaya A, Goenawan H, Setiawan I, Gunadi JW, Limyati Y, Lesmana R. Elaborating the physiological role of YAP as a glucose metabolism regulator: a systematic review. Cell Physiol Biochem. 2021;55:193\u2013205.","journal-title":"Cell Physiol Biochem"},{"key":"3369_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1152\/physrev.00043.2019","volume":"101","author":"JC Chatham","year":"2021","unstructured":"Chatham JC, Zhang J, Wende AR. Role of O-linked N-acetylglucosamine protein modification in cellular (patho) physiology. Physiol Rev. 2021;101:427\u201393.","journal-title":"Physiol Rev"},{"key":"3369_CR26","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1021\/pr2002726","volume":"10","author":"P Zhao","year":"2011","unstructured":"Zhao P, Viner R, Teo CF, Boons GJ, Horn D, Wells L. Combining high-energy C-trap dissociation and electron transfer dissociation for protein O-GlcNAc modification site assignment. J Proteome Res. 2011;10:4088\u2013104.","journal-title":"J Proteome Res"},{"key":"3369_CR27","doi-asserted-by":"crossref","unstructured":"Yoo TY, Mitchison TJ. O-GlcNAc modification of nuclear pore complexes accelerates bidirectional transport. J Cell Biol. 2021;220:e202010141.","DOI":"10.1083\/jcb.202010141"},{"key":"3369_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10624","volume":"7","author":"D Niopek","year":"2016","unstructured":"Niopek D, Wehler P, Roensch J, Eils R, Di Ventura B. Optogenetic control of nuclear protein export. Nat Commun. 2016;7:10624.","journal-title":"Nat Commun"},{"key":"3369_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tips.2024.11.002","volume":"46","author":"YF Chen","year":"2025","unstructured":"Chen YF, Adams DJ. Therapeutic targeting of exportin-1 beyond nuclear export. Trends Pharm Sci. 2025;46:20\u201331.","journal-title":"Trends Pharm Sci"},{"key":"3369_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.14348\/molcells.2017.2309","volume":"40","author":"A Ali","year":"2017","unstructured":"Ali A, Kim SH, Kim MJ, Choi MY, Kang SS, Cho GJ, et al. O-GlcNAcylation of NF-\u03baB promotes lung metastasis of cervical cancer cells via upregulation of CXCR4 expression. Mol Cells. 2017;40:476\u201384.","journal-title":"Mol Cells"},{"key":"3369_CR31","doi-asserted-by":"publisher","first-page":"44596","DOI":"10.18632\/oncotarget.10112","volume":"7","author":"M Kim","year":"2016","unstructured":"Kim M, Kim YS, Kim H, Kang MY, Park J, Lee DH, et al. O-linked N-acetylglucosamine transferase promotes cervical cancer tumorigenesis through human papillomaviruses E6 and E7 oncogenes. Oncotarget. 2016;7:44596\u2013607.","journal-title":"Oncotarget"},{"key":"3369_CR32","first-page":"1121","volume":"40","author":"G Zhu","year":"2019","unstructured":"Zhu G, Qian M, Lu L, Chen Y, Zhang X, Wu Q, et al. O-GlcNAcylation of YY1 stimulates tumorigenesis in colorectal cancer cells by targeting SLC22A15 and AANAT. Carcinogenesis. 2019;40:1121\u201331.","journal-title":"Carcinogenesis"},{"key":"3369_CR33","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/jcmm.14038","volume":"23","author":"N Wu","year":"2019","unstructured":"Wu N, Jiang M, Han Y, Liu H, Chu Y, Liu H, et al. O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5. J Cell Mol Med. 2019;23:1354\u201362.","journal-title":"J Cell Mol Med"},{"key":"3369_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-021-00810-4","volume":"8","author":"E Wulff-Fuentes","year":"2021","unstructured":"Wulff-Fuentes E, Berendt RR, Massman L, Danner L, Malard F, Vora J, et al. The human O-GlcNAcome database and meta-analysis. Sci Data. 2021;8:25.","journal-title":"Sci Data"},{"key":"3369_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1146\/annurev-biochem-062917-011901","volume":"88","author":"DH Lin","year":"2019","unstructured":"Lin DH, Hoelz A. The structure of the nuclear pore complex (an update). Annu Rev Biochem. 2019;88:725\u201383.","journal-title":"Annu Rev Biochem"},{"key":"3369_CR36","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/ejhg.2016.25","volume":"24","author":"V Nofrini","year":"2016","unstructured":"Nofrini V, Di Giacomo D, Mecucci C. Nucleoporin genes in human diseases. Eur J Hum Genet. 2016;24:1388\u201395.","journal-title":"Eur J Hum Genet"},{"key":"3369_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","volume":"17","author":"S Hutten","year":"2007","unstructured":"Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17:193\u2013201.","journal-title":"Trends Cell Biol"},{"key":"3369_CR38","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1074\/jbc.M112.433243","volume":"288","author":"S Roloff","year":"2013","unstructured":"Roloff S, Spillner C, Kehlenbach RH. Several phenylalanine-glycine motives in the nucleoporin Nup214 are essential for binding of the nuclear export receptor CRM1. J Biol Chem. 2013;288:3952\u201363.","journal-title":"J Biol Chem"},{"key":"3369_CR39","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.celrep.2015.09.042","volume":"13","author":"SA Port","year":"2015","unstructured":"Port SA, Monecke T, Dickmanns A, Spillner C, Hofele R, Urlaub H, et al. Structural and functional characterization of CRM1-Nup214 interactions reveals multiple FG-binding sites involved in nuclear export. Cell Rep. 2015;13:690\u2013702.","journal-title":"Cell Rep"},{"key":"3369_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.biochem.7b00871","volume":"57","author":"HJ Tarbet","year":"2018","unstructured":"Tarbet HJ, Toleman CA, Boyce M. A sweet embrace: control of protein-protein interactions by O-linked \u03b2-N-acetylglucosamine. Biochemistry. 2018;57:13\u201321.","journal-title":"Biochemistry"},{"key":"3369_CR41","doi-asserted-by":"crossref","unstructured":"K\u0131rl\u0131 K, Karaca S, Dehne HJ, Samwer M, Pan KT, Lenz C, et al. A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. Elife. 2015;4:e11466.","DOI":"10.7554\/eLife.11466"},{"key":"3369_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1\u2014from biology to targeted therapy. Nat Rev Clin Oncol. 2021;18:152\u201369.","journal-title":"Nat Rev Clin Oncol"},{"key":"3369_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1684","volume":"14","author":"C Lai","year":"2024","unstructured":"Lai C, Xu L, Dai S. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials. Clin Transl Med. 2024;14:e1684.","journal-title":"Clin Transl Med"},{"key":"3369_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2023.100963","volume":"47","author":"G Bogani","year":"2023","unstructured":"Bogani G, Monk BJ, Coleman RL, Vergote I, Oakin A, Ray-Coquard I, et al. Selinexor in patients with advanced and recurrent endometrial cancer. Curr Probl Cancer. 2023;47:100963.","journal-title":"Curr Probl Cancer"},{"key":"3369_CR45","doi-asserted-by":"publisher","first-page":"13119","DOI":"10.18632\/oncotarget.3761","volume":"6","author":"M De Cesare","year":"2015","unstructured":"De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, et al. Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 2015;6:13119\u201332.","journal-title":"Oncotarget"},{"key":"3369_CR46","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1091\/mbc.E18-02-0096","volume":"29","author":"SC Fu","year":"2018","unstructured":"Fu SC, Fung HYJ, Ca\u011fatay T, Baumhardt J, Chook YM. Correlation of CRM1-NES affinity with nuclear export activity. Mol Biol Cell. 2018;29:2037\u201344.","journal-title":"Mol Biol Cell"},{"key":"3369_CR47","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1073\/pnas.1217203110","volume":"110","author":"Q Sun","year":"2013","unstructured":"Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA. 2013;110:1303\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3369_CR48","doi-asserted-by":"publisher","first-page":"D462","DOI":"10.1093\/nar\/gkae1032","volume":"53","author":"S Okuda","year":"2025","unstructured":"Okuda S, Yoshizawa AC, Kobayashi D, Takahashi Y, Watanabe Y, Moriya Y, et al. jPOST environment accelerates the reuse and reanalysis of public proteome mass spectrometry data. Nucleic Acids Res. 2025;53:D462\u201367.","journal-title":"Nucleic Acids Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03369-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03369-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03369-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:02:27Z","timestamp":1776171747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03369-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,5]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03369-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethics committee of Aichi Cancer Center (approval number IR041047; approval date, September 2022) and performed in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the ethics committee because of the minimal risk involved. All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of the Aichi Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}